EVOLUT Low-Risk Trial data: "We see what we want to see!"

Pradeep Narayan

doi:10.1007/s12055-023-01674-6

EVOLUT Low-Risk Trial data: "We see what we want to see!"

Indian J Thorac Cardiovasc Surg. 2024 Mar;40(2):262-264. doi: 10.1007/s12055-023-01674-6. Epub 2024 Jan 3.

Author

Pradeep Narayan¹

Affiliation

¹ Department of Cardiac Surgery, Rabindranath Tagore International Institute of Cardiac Sciences, Narayana Health, 124, EM Bypass, Mukundapur, Kolkata, 700099 India.

PMID: 38389759
PMCID: PMC10879050 (available on 2025-03-01)
DOI: 10.1007/s12055-023-01674-6

Abstract

In the 4-year update of the EVOLUT Low-Risk Trial (NCT02701283), the authors highlight a non-significant improvement in the primary endpoint and a statistically significant, yet clinically irrelevant, enhancement in hemodynamics with transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR). Overlooking the concurrent surgical procedures in SAVR patients, mortality rates remain similar at 4 years. Unaddressed is the substantial increase in permanent pacemaker implantations with TAVR and the fate of patients with paravalvular leaks.

Keywords: EVOLUT; SAVR; TAVR.

© Indian Association of Cardiovascular-Thoracic Surgeons 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.